Published in final edited form as:
Tetrahedron Lett. 2011 December 7; 52(49): 6643–6645. doi:10.1016/j.tetlet.2011.10.012.

Multicomponent Synthesis of 2,3-Dihydrochromeno[4,3-*d*]pyrazolo[3,4-*b*]pyridine-1,6-diones: A Novel Heterocyclic Scaffold with Antibacterial Activity

Liliya V. Frolova[a], **Indranil Malik**[b], **Pavel Y. Uglinskii**[c], **Snezna Rogelj**[b], **Alexander Kornienko**[a], and **Igor V. Magedov**[a,*]

[a]Department of Chemistry, New Mexico Institute of Mining and Technology, Socorro, New Mexico 87801, USA

[b]Department of Biology, New Mexico Institute of Mining and Technology, Socorro, New Mexico 87801, USA

[c]Department of Organic Chemistry, Timiryazev Agriculture Academy, Moscow 127550, Russia

Abstract

A multicomponent reaction of 3-aminopyrazol-5-ones with substituted salicylic aldehydes and acetylacetic ester leading to the formation of novel 2,3-dihydrochromeno[4,3-*d*]pyrazolo[3,4-*b*]pyridine-1,6-diones was discovered. The elucidation of the reaction scope revealed that 5-aminopyrazoles, 3-amino-1,2,4-triazoles and 6-aminouracil could be used as the heterocyclic amine component. Selected heterocyclic products were found to possess notable antibacterial activities.

Keywords

MCR; aminopyrazole; antibacterial activity; benzopyranopyridines

Multicomponent reactions (MCRs) are a powerful synthetic tool. In this approach, three or more reactants are combined together in a single reaction flask to generate a product incorporating most of the atoms contained in the starting materials. MCRs have been widely exploited in combinatorial and medicinal chemistry and they are particularly useful for the preparation of polycondensed heterocyclic systems.[1]

In this connection, hetero-fused benzopyranopyridines are a poorly studied class of polycondensed heterocycles (Figure 1a). Only four types of scaffolds (**A, C, D, E**) have been reported in the literature out of the six possible molecular frameworks (**A–F**) and the synthetic approaches used by researchers to access these structures have invariably involved multistep sequences.[2–13] Importantly, compounds based on these heterocyclic systems have been reported to possess anti-inflammatory,[2] antibacterial[2,10] and antifungal[10] activities (Figure 1b). As part of our efforts aimed at the discovery of MCRs to synthesize compounds with anticancer and antibacterial activities,[14–25] we discovered a new approach to access the

*Corresponding author. Tel.: +1 575 835 6886; fax: +1 575 835 5364; imagedov@nmt.edu.

type **C** molecular framework. Herein, we describe this synthetic finding as well as the preliminary biological evaluation of compounds synthesized using this new method.

Specifically, we found that combining 3-aminopyrazol-5-ones **1a–c** with substituted salicylic aldehydes **2a–h** and acetylacetic ester (**3**) leads to the formation of 2,3-dihydrochromeno[4,3-*d*]pyrazolo[3,4-*b*]pyridin-1,6-diones **4a–o** (Scheme 1). Generally good yields of these polyheterocyclic compounds are obtained when mixtures of the three starting components and one drop of piperidine are refluxed in acetic acid for 3 h. This three-component process works well any tested combination of substituted salicylic aldehydes **2** and 3-aminopyrazol-5-ones **1**. The desired products precipitate upon cooling of the reaction mixtures and a simple filtration provides analytically pure material (> 95%).[26]

We propose that the mechanistic route for this transformation involves an *in situ* formation of 3-acetylcoumarins **5** and their subsequent condensation with aminopyrazolones **1** (Scheme 2). Indeed, we demonstrated that this process can be conducted stepwise by condensing salicylic aldehyde (**2a**) with acetylacetic ester (**3**) and isolating 3-acetylcoumarin (**5a**) in a quantitative yield (Scheme 2a). **5a** was further reacted with 3-amino-1*H*-pyrazol-5(4*H*)-one (**1a**) under the same reaction conditions and gave a comparable yield of polyheterocycle **4a** (Scheme 2b).

To investigate the scope of this process with respect to the acetylacetic ester component, we attempted to replace it with ethyl benzoylacetate. However, the reaction was unsuccessful in this case, possibly due to the change in electronic and steric environment of the ketone carbonyl. On the other hand, the replacement of the aminoheterocyclic component was much more forgiving. Thus, we explored the corresponding reactions of 5-amino-1-phenyl-3-methylpyrazole (**6**), 3-amino-1,2,4-triazole (**7**) and 6-aminouracil (**8**, Scheme 3). The desired polyheterocycles **9**, **10** and **11** were obtained in acceptable yields, indicating the potential of this MCR to be used as a general method to access polyheterocyclic scaffolds **C** (see Figure 1).[27]

The initial evaluation of the synthesized polyheterocycles for antimicrobial activities revealed significant antibacterial properties associated with several analogues specifically against Gram-(+) strains. Thus, compounds **4i** and **4o** inhibited the growth of *S. epidermidis* with the MIC values of 6.3 μM and 25 μM, respectively. Furthermore, heterocycle **4i** was also effective against methicillin-resistant *S. aureus* (MRSA), inhibiting the growth of this clinically important nosocomial pathogen with an MIC value of 25 μM. Further exploration of the MCR scope and antimicrobial activities associated with these novel heterocyclic structures are underway and will be reported in due course.

Acknowledgments

US National Institutes of Health (grants RR-16480 and CA-99957) are gratefully acknowledged for financial support of this work.

References and notes

1. For a recent review, see: Syamala M. Org. Prep. Proceed. Int. 2009; 41:1.
2. Khan IA, Kulkarni MV, Gopal M, Shahabuddin MS, Sun C-M. Bioorg. Med. Chem. Lett. 2005; 15:3584. [PubMed: 15967664]
3. Frasinyuk MS, Gorelov SV, Bondarenko SP, Khilya VP. Chem. Heterocycl. Compd. 2009; 45:1261.
4. Gohain M, Prajapati D, Gogoi BJ, Sandhu JS. Synlett. 2004:1179.
5. Ismail NA, Khalifa F, Magd ED, Asmaa A. Heterocycles. 1991; 32:1101.
6. Gautam DR, Protopappas J, Fylaktakidou KC, Litinas KE, Nicolaides DN, Tsoleridis CA. Tetrahedron Lett. 2009; 50:448.

7. Prasad KR, Darbarwar M. Org. Prep. Proceed. Int. 1995; 27:547.
8. Prasad KR, Darbarwar M. Syn. Commun. 1992; 22:2479.
9. Siddiqui ZN, Praveen S, Farooq F. Chem. Papers. 2010; 64:818.
10. Ramalingam P, Ganapaty S, Rao CB, Ravi TK. Indian J. Heterocycl. Chem. 2006; 15:359.
11. Brownsort PA, Paton RM, Stutherland AG. J. Chem. Soc., Perkin Trans. 1. 1989:1679.
12. Schurreit T. Arch. Pharm. 1987; 320:500.
13. Mogilaiah K, Sreenivasulu B. Indian J. Chem., Sec. B. Org. Chem. Incl. Med. Chem. 1982; 21B: 582.
14. Evdokimov NM, Magedov IV, Kireev AS, Kornienko A. Org. Lett. 2006; 9:899. [PubMed: 16494469]
15. Evdokimov NM, Kireev AS, Yakovenko AA, Antipin MY, Magedov IV, Kornienko A. Tetrahedron Lett. 2006; 47:9309.
16. Evdokimov NM, Kireev AS, Yakovenko AA, Antipin MY, Magedov IV, Kornienko A. J. Org. Chem. 2007; 72:3443. [PubMed: 17408286]
17. Magedov IV, Manpadi M, Rozhkova E, Przheval'skii NM, Rogelj S, Shors ST, Steelant WFA, Van Slambrouck S, Kornienko A. Bioorg. Med. Chem. Lett. 2007; 17:1381. [PubMed: 17188868]
18. Magedov IV, Manpadi M, Van Slambrouck S, Steelant WFA, Rozhkova E, Przhevalískii NM, Rogelj S, Kornienko A. J. Med. Chem. 2007; 50:5183. [PubMed: 17894480]
19. Magedov IV, Manpadi M, Evdokimov NM, Elias EM, Rozhkova E, Ogasawara MA, Bettale JD, Przeval'skii NM, Rogelj S, Kornienko A. Bioorg. Med. Chem. Lett. 2007; 17:3872. [PubMed: 17512729]
20. Manpadi M, Uglinskii PY, Rastogi SK, Cotter KM, Wong Y-SC, Anderson LA, Ortega AJ, Van slambrouck S, Steelant WFA, Rogelj S, Tongwa P, Antipin MY, Magedov IV, Kornienko A. Org. Biomol. Chem. 2007; 5:3865. [PubMed: 18004468]
21. Magedov IV, Luchetti G, Evdokimov NM, Manpadi M, Steelant WFA, Van slambrouck S, Tongwa P, Antipin MYu, Kornienko A. Bioorg. Med. Chem Lett. 2008; 18:1392. [PubMed: 18221874]
22. Magedov IV, Manpadi M, Ogasawara MA, Dhawan AS, Rogelj S, Van slambrouck S, Steelant WFA, Evdokimov NM, Uglinskii PY, Elias EM, Knee EJ, Tongwa P, Antipin MY, Kornienko A. J. Med. Chem. 2008; 51:2561. [PubMed: 18361483]
23. Frolova LV, Evdokimov NM, Hayden K, Malik I, Rogelj S, Kornienko A, Magedov IV. Org. Lett. 2011; 13:1118. [PubMed: 21268660]
24. Evdokimov NM, Van slambrouck S, Heffeter P, Tu L, Le Calve B, Lamoral-Theys D, Hooten CJ, Uglinskii PY, Rogelj S, Kiss R, Steelant WFA, Berger W, Bologa CJ, Yang JJ, Kornienko A, Magedov IV. J. Med. Chem. 2011; 54:2012. [PubMed: 21388138]
25. Magedov IV, Frolova L, Manpadi M, Bhoga UD, Tang H, Evdokimov NM, George O, Georgiou KH, Renner S, Getlik M, Kinnibrugh TL, Fernandes MA, Van slambrouck S, Steelant WFA, Shuster CB, Rogelj S, van Otterlo WAL, Kornienko A. J. Med. Chem. 2011; 54:4234. [PubMed: 21615090]
26. *Synthetic procedure **(4a–o, 9, 10, 11)***: To a mixture of acetylacetic ester, substituted salicylic aldehyde (**2a–h**) and aminoheterocycle (**1a–c, 6, 7, 8**) was added 1 drop of piperidine. The mixture was stirred for 15 min after which time acetic acid (5 mL) was added and the reaction mixture was refluxed for 3–12 hours. The desired products precipitate upon cooling of the reaction mixtures, and a simple filtration and washing with ethanol provides analytically pure material (> 95%). *Selected characterization data*: **4a**: 60%; ^{1}H NMR (DMSO-d_6, 373 K) δ 9.95 (d, *J*=7.98 Hz, 1H), 7.67 (t, *J*=7.14 Hz, 1H), 7.42-7.36 (m, 2H), 2.96 (s, 3H); ^{13}C NMR (DMSO-d_6, 373 K) δ 164.9, 157.3, 152.9, 133.9, 131.9, 124.6, 117.6, 117.1, 113.7, 28.1; HRMS *m/z* (ESI) calcd for $C_{14}H_9N_3O_3 - H^-$ 266.0566, found 266.0562. **9**: 65%; ^{1}H NMR (DMSO-d_6, 373 K) δ 8.33 (d, *J*=7.68 Hz, 1H), 8.19 (d, *J*=7.17 Hz, 2H), 7.73 (t, *J*=7.24 Hz, 1H), 7.59-7.30 (m, 6H), 3.36 (s, 3H), 3.02 (s, 3H); ^{13}C NMR (DMSO-d_6, 373 K) δ 162.9, 159.8, 152.9, 143.8, 139.2, 133.9, 130.4, 129.8, 129.6, 127.3, 124.8, 122.5, 122.2 117.6, 117.6, 111.2, 28.0, 19.3; HRMS *m/z* (ESI) calcd for $C_{21}H_{15}N_3O_2 + Na^+$ 364.1062, found 364.1067. **10**: 53%; ^{1}H NMR (DMSO-d_6, 373 K) δ 9.79 (d, *J*=8.25 Hz, 1H), 8.94 (s, 1H), 7.93 (t, *J*=7.68 Hz, 1H), δ 7.65 (d, *J*=8.25 Hz, 1H), 7.59 (d, *J*=7.98 Hz, 1H), 3.11 (s, 3H); ^{13}C NMR (DMSO-d_6, 373 K) δ 167.6, 158.3, 156.2, 154.7, 136.5,

130.6, 126.0, 118.0, 117.6, 112.3, 106.0, 27.9; HRMS *m/z* (ESI) calcd for $C_{13}H_8N_4O_2$ + Na^+ 275.0545, found 275.0537. **11**: 57%; ^{1}H NMR (DMSO-d_6, 323 K) δ 10.27 (bs, 1H), 9.87 (bs, 1H) 8.17 (d, *J*=8.22 Hz, 1H), 7.65 (t, *J*=8.22 Hz, 1H), 7.37 (d, *J*=8.22 Hz, 1H), 7.27 (t, *J*=8.25 Hz, 1H), 3.05 (s, 3H); ^{13}C NMR (DMSO-d_6, 323 K) δ 169.1, 166.3, 162.4, 159.1, 156.2, 152.9, 150.7, 134.4, 132.8, 123.6, 117.0, 116.1, 113.1, 103.2, 27.7; HRMS *m/z* (ESI) calcd for $C_{15}H_{10}N_3O_4$ + H^+ 296.0671, found 296.0670.

27. As our work was in progress, a similar reaction between salicylic aldehyde, acetylacetic ester and 3-methyl-5-aminopyrazole leading to the formation 1,4-dihydropyridine analogs of **9**, appeared in the literature: Svetlik J, Veizerova L, Mayer TU, Catarinella M. Bioorg. Med. Chem. Lett. 2010; 20:4073. [PubMed: 20542426]



Figure 1.

(a) Six possible types of hetero-fused benzopyranopyridines (b) and representative compounds with biological activities



1a R_1 = H
1b R_1 = Ph
1c R_1 = 2,5-di-Cl-Ph

2a R_2 = R_3 = H
2b R_2 = 5-Br, R_3 = H
2c R_2 = 3-Cl, R_3 = 5-Cl
2d R_2 = 5-NO_2, R_3 = H
2e R_2 = 5-Cl, R_3 = H
2f R_2 = 5-Me, R_3 = H
2g R_2 = 3-OMe, R_3 = H
2h R_2 = 4-OH, R_3 = H

4a R_1 = R_2 = R_3 = H	60%
4b R_1 = R_3 = H, R_2 = 10-Br	67%
4c R_1 = R_3 = H, R_2 = 10-NO_2	77%
4d R_1 = R_3 = H, R_2 = 10-Cl	73%
4e R_1 = R_3 = H, R_2 = 8-MeO	63%
4f R_1 = R_3 = H, R_2 = 9-OH	53%
4g R_1 = Ph, R_2 = R_3 = H	70%
4h R_1 = Ph, R_2 = 10-Br, R_3 = H	74%
4i R_1 = Ph, R_2 = 8-Cl, R_3 = 10-Cl	82%
4j R_1 = Ph, R_2 = 10-NO_2, R_3 = H	79%
4k R_1 = Ph, R_2 = 10-Cl, R_3 = H	76%
4l R_1 = Ph, R_2 = 10-Me, R_3 = H	71%
4m R_1 = Ph, R_2 = 8-MeO, R_3 = H	64%
4n R_1 = 2,5-di-Cl-Ph, R_2 = 10-Me, R_3 = H	74%
4o R_1 = 2,5-di-Cl-Ph, R_2 = 8-MeO, R_3 = H	66%

Scheme 1.
MCR synthesis of 2,3-dihydrochromeno[4,3-*d*]pyrazolo[3,4-*b*]pyridin-1,6-diones **4a–o**



Scheme 2.
3-Acetylcoumarins as intermediates in the discovered MCR



Scheme 3.
MCR synthesis of polyheterocycles **9, 10** and **11**